Yue Shentu

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson et al. · New England Journal of Medicine · 2016 · 10.1K citations · Full text

Medicine, Oncology, Pharmacology +17

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Roy S. Herbst, Dong‐Wan Kim, Enriqueta Felip et al. · The Lancet · 2015 · 6.5K citations

Medicine, Oncology, Pharmacology +14

Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes

Gary Meininger, Russell Scott, Maria Alba et al. · Diabetes Care · 2011 · 217 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC).

Luis Paz‐Ares, Alexander Luft, Ali Tafreshi et al. · Journal of Clinical Oncology · 2018 · 121 citations

Medicine, Oncology, Pharmacology +16

Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial

Roy S. Herbst, José Luis Perez‐Gracia, Enriqueta Felip et al. · Annals of Oncology · 2019 · 105 citations · Full text

Medicine, Oncology, Pharmacotherapy +17